In Situ Gene Therapy for Prostate Cancer: Development of Systemic Anti-Tumor Immunity

Abstract

Although to our knowledge there are no dearly defined tumor antigens for prostate cancer, based on our preliminary data we of the opinion that specific gene-modified cell-based immunotherapy protocols could result in the generation of a systemic anti-metastatic immune response. We have shown that IL-12+B7 transduced antigen-presenting cells (APC) can effectively induce an anti-tumor immunity; that IL-12+B7 modified prostate cancer cell vaccine strategies can generate a systemic anti-tumor immune response; and, that IL-12+B7 gene delivery has specific therapeutic effects against bone metastases. We proposed to test the efficacy of specific therapeutic approaches incorporating novel biological concepts of IL-12 gene modified cell-based therapy using preclinical models of metastatic prostate cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2003
Accession Number
ADA415519

Entities

People

  • Timothy C Thompson

Organizations

  • Baylor College of Medicine

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Blood
  • Blood Cells
  • Bone Marrow
  • Bone Marrow Cells
  • Cells
  • Gene Therapy
  • Lymphatic System
  • Lymphocytes
  • Mononuclear Phagocyte System
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Stem Cells
  • Therapy
  • Tissues

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech